Skip to main content
Erschienen in: World Journal of Urology 3/2006

01.08.2006 | Topic Paper

Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer

verfasst von: Stefan Machtens, Rolf Baumann, Jörn Hagemann, Antje Warszawski, Andreas Meyer, Johann H. Karstens, Udo Jonas

Erschienen in: World Journal of Urology | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Permanent interstitial brachytherapy represents the most conformal form of radiation therapy of the prostate and the number of patients with prostate cancers treated with permanent radioactive implants is increasing world wide. In the meanwhile long-term data on tumor control and treatment morbidity become available. Biochemical and clinical tumor control appears to be as effective as after radical prostatectomy or external beam radiation therapy in early prostate cancer. The risk of postreatment urinary incontinence and bowel dysfunction is low and erectile function can be preserved in the majority of patients. However, prostate brachytherapy requires a careful selection of patients as pretreatment factors predict for long-term outcome. The need for combined modality approaches in intermediate and high-risk patients remains controversely discussed. The continous refinement of intraoperative planning techniques and the elucidation of the etiology of urinary, sexual, and bowel dysfunction should result in further improvements in biochemical outcomes and decreased morbidity. Improved and standardized postimplantation evaluation will make outcome data more reliable and comparable.
Literatur
1.
Zurück zum Zitat Pasteau O (1911) Traitement du cancer de la prostate par le radium. Rev Mal Nutr 1911:363–367 Pasteau O (1911) Traitement du cancer de la prostate par le radium. Rev Mal Nutr 1911:363–367
2.
Zurück zum Zitat Paschkis R (1911) Wien Klin Wochenschr 24:1562–1564 Paschkis R (1911) Wien Klin Wochenschr 24:1562–1564
3.
Zurück zum Zitat Barringer B (1917) Radium in the treatment of carcinoma of the bladder and prostate: review of 1y ear’s work. JAMA 68:1227–1230 Barringer B (1917) Radium in the treatment of carcinoma of the bladder and prostate: review of 1y ear’s work. JAMA 68:1227–1230
4.
Zurück zum Zitat Flocks RH, Kerr HD, Elkins HB, Culp DA (1954) The treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au198): a follow-up report. J Urol 71:628–633PubMed Flocks RH, Kerr HD, Elkins HB, Culp DA (1954) The treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au198): a follow-up report. J Urol 71:628–633PubMed
5.
Zurück zum Zitat Whitmore WF Jr, Hilaris B, Grabstald H (1972) Retropubic implantation of Iodine 125 in the treatment of prostate cancer. J Urol 108:918–920PubMed Whitmore WF Jr, Hilaris B, Grabstald H (1972) Retropubic implantation of Iodine 125 in the treatment of prostate cancer. J Urol 108:918–920PubMed
6.
Zurück zum Zitat Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I (1983) Transperineal 125 Iodine seed implantation in prostatic cancer guided by transrectal ultrasoundsonography. J Urol 130:283–2861PubMed Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I (1983) Transperineal 125 Iodine seed implantation in prostatic cancer guided by transrectal ultrasoundsonography. J Urol 130:283–2861PubMed
7.
Zurück zum Zitat Ling CC (1992) Permanent implants using Au-198, Pd-103 and I-125: a radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23:81–87PubMed Ling CC (1992) Permanent implants using Au-198, Pd-103 and I-125: a radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23:81–87PubMed
8.
Zurück zum Zitat Nath R, Anderson LL, Luxton G (1995) Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group o.43. American Association of Physicists in Medicine. Med Phys 22:209–234PubMedCrossRef Nath R, Anderson LL, Luxton G (1995) Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group o.43. American Association of Physicists in Medicine. Med Phys 22:209–234PubMedCrossRef
9.
Zurück zum Zitat Beyer D, Nath R, Buller W (2000) American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103) palladium brachytherapy. Int J Radiat Oncol Biol Phys 47:273–275PubMedCrossRef Beyer D, Nath R, Buller W (2000) American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103) palladium brachytherapy. Int J Radiat Oncol Biol Phys 47:273–275PubMedCrossRef
10.
Zurück zum Zitat Williamson JF, Coursey BM, deWerd LA (2000) Recommendations of the American association of physicists in medicine on 103Pd interstitial source calibration and dosimetry: Implications for dose specification and prescription. Med Phys 27:634–642PubMedCrossRef Williamson JF, Coursey BM, deWerd LA (2000) Recommendations of the American association of physicists in medicine on 103Pd interstitial source calibration and dosimetry: Implications for dose specification and prescription. Med Phys 27:634–642PubMedCrossRef
11.
Zurück zum Zitat Blasko JC, Wallner K, Grimm PD, Ragde H (1995) PSA-based disease control following ultrasound—guided 125J implantation for stage T1/T2 prostatic carcinoma. J Urol 154:1096–1099PubMedCrossRef Blasko JC, Wallner K, Grimm PD, Ragde H (1995) PSA-based disease control following ultrasound—guided 125J implantation for stage T1/T2 prostatic carcinoma. J Urol 154:1096–1099PubMedCrossRef
12.
Zurück zum Zitat Stock RG, Stone NN, Wesson MF, DeWyngaert JK (1995) A modified technique allowing interactive ultrasound – guided three – dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32:219–225PubMed Stock RG, Stone NN, Wesson MF, DeWyngaert JK (1995) A modified technique allowing interactive ultrasound – guided three – dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32:219–225PubMed
13.
Zurück zum Zitat Quimby EH (1932) The grouping of radium tubes in packs and plaques to produce the desired distribution of radiation. Am J Roentgenol 27:18–36 Quimby EH (1932) The grouping of radium tubes in packs and plaques to produce the desired distribution of radiation. Am J Roentgenol 27:18–36
14.
Zurück zum Zitat Paterson R, Parker HM (1943) A dosage system for gamma-ray therapy 1+2 . Br J Radiol 7:592–632CrossRef Paterson R, Parker HM (1943) A dosage system for gamma-ray therapy 1+2  . Br J Radiol 7:592–632CrossRef
15.
Zurück zum Zitat Prete JJ, Prestidge BR, Bice WS, Friedland JL, Stock RG, Grimm PD (1998) A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40:1001–1008PubMedCrossRef Prete JJ, Prestidge BR, Bice WS, Friedland JL, Stock RG, Grimm PD (1998) A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 40:1001–1008PubMedCrossRef
16.
Zurück zum Zitat Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y (2000) American brachytherapy guidelines for post-implant dosimetry for prostate brachytherapy. Int J Radiat Oncol Biol Phys 46:221–230PubMedCrossRef Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y (2000) American brachytherapy guidelines for post-implant dosimetry for prostate brachytherapy. Int J Radiat Oncol Biol Phys 46:221–230PubMedCrossRef
17.
Zurück zum Zitat Stock RG, Stone NN (2002) Importance of post-implant dosimetry in permanent brachytherapy. Eur Urol 41:434–439PubMedCrossRef Stock RG, Stone NN (2002) Importance of post-implant dosimetry in permanent brachytherapy. Eur Urol 41:434–439PubMedCrossRef
18.
Zurück zum Zitat Waterman FM, Yue N, Corn BW, Dicker AP (1998) Edema associated with I-125 or PD-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41:1069–1077PubMed Waterman FM, Yue N, Corn BW, Dicker AP (1998) Edema associated with I-125 or PD-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41:1069–1077PubMed
19.
Zurück zum Zitat Stock RG, Stone NN, Tabert A, Ianuzzi C, DeWyngaert JK (1998) A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101–108PubMed Stock RG, Stone NN, Tabert A, Ianuzzi C, DeWyngaert JK (1998) A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101–108PubMed
20.
Zurück zum Zitat Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321PubMedCrossRef Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321PubMedCrossRef
21.
Zurück zum Zitat Wirth MP, Hermann T, Alken P, Kovacs G, Müller R-P, Hakenberg OW, Ahlemann L, Schalkhäuser K (2002) Empfehlungen zur Durchführung der alleinigen, permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Strahlenther Onkol 178:115–119PubMed Wirth MP, Hermann T, Alken P, Kovacs G, Müller R-P, Hakenberg OW, Ahlemann L, Schalkhäuser K (2002) Empfehlungen zur Durchführung der alleinigen, permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Strahlenther Onkol 178:115–119PubMed
22.
Zurück zum Zitat Grimm PD, Blasko JC, Sylvester JE (2001) 10y ear biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 51:31–40 Grimm PD, Blasko JC, Sylvester JE (2001) 10y ear biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 51:31–40
23.
Zurück zum Zitat Blasko JC, Grimm PD, Sylvester JE (2000) Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46:839–850PubMed Blasko JC, Grimm PD, Sylvester JE (2000) Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46:839–850PubMed
24.
Zurück zum Zitat Ragde H, Korb L, Elgamal AA (2000) A 12 year follow-up after transperineal brachytherapy of localized prostate cancer. J Urol 163(4, Suppl I):336–337 Ragde H, Korb L, Elgamal AA (2000) A 12 year follow-up after transperineal brachytherapy of localized prostate cancer. J Urol 163(4, Suppl I):336–337
25.
Zurück zum Zitat Brachman DG, Thomas T, Hilbe J, Beyer DC (2000) Failure-free survival following brachyherapy alone or external beam irridiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 48:111–117PubMedCrossRef Brachman DG, Thomas T, Hilbe J, Beyer DC (2000) Failure-free survival following brachyherapy alone or external beam irridiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 48:111–117PubMedCrossRef
26.
Zurück zum Zitat Grimm PD, Blasko JC, Sylvester JE (2001) 10y ear biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 51:31–40 Grimm PD, Blasko JC, Sylvester JE (2001) 10y ear biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 51:31–40
27.
Zurück zum Zitat Beyer DC, Thomas T, Hilbe J, Swenson V (2003) Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2(2):77–84PubMedCrossRef Beyer DC, Thomas T, Hilbe J, Swenson V (2003) Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2(2):77–84PubMedCrossRef
28.
Zurück zum Zitat Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71(1):29–33PubMedCrossRef Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71(1):29–33PubMedCrossRef
29.
Zurück zum Zitat Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation and combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58(1):25–33PubMedCrossRef Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation and combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58(1):25–33PubMedCrossRef
30.
Zurück zum Zitat Sylvester JE, Blasko JC, Grimm R, Meier R, Spiegel JF, Malmgren JA (2004) Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy. J Clin Oncol 22(145):4567 Sylvester JE, Blasko JC, Grimm R, Meier R, Spiegel JF, Malmgren JA (2004) Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy. J Clin Oncol 22(145):4567
31.
Zurück zum Zitat Potters C, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E (2005) 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173(5):1562–1566PubMedCrossRef Potters C, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E (2005) 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173(5):1562–1566PubMedCrossRef
32.
Zurück zum Zitat Stone NN, Stock RG, Unger P (2005) Intermediate term biochemical-free progression andlocal control following 125 Iodine brachytherapy for prostate cancer. J Urol 173:803–807PubMedCrossRef Stone NN, Stock RG, Unger P (2005) Intermediate term biochemical-free progression andlocal control following 125 Iodine brachytherapy for prostate cancer. J Urol 173:803–807PubMedCrossRef
33.
34.
Zurück zum Zitat Sharkey J, Chovnick SD, Behar RD (2000) Minimally invasive treatment for localized adenocarcinoma of the prostate. Review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 14:343–354PubMedCrossRef Sharkey J, Chovnick SD, Behar RD (2000) Minimally invasive treatment for localized adenocarcinoma of the prostate. Review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 14:343–354PubMedCrossRef
35.
Zurück zum Zitat Potters L, Cha C, Oshinsky G (1999) Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 5:301–306PubMed Potters L, Cha C, Oshinsky G (1999) Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 5:301–306PubMed
36.
Zurück zum Zitat Sylvester J, Blasko JC, Grimm PD (2000) Short-course androgen ablation combined with external-beam radiation therapy and low-dose rate permanent brachytherapy in early-stage prostate cancer: A matched subset analysis. Mol Urol 3:155–160 Sylvester J, Blasko JC, Grimm PD (2000) Short-course androgen ablation combined with external-beam radiation therapy and low-dose rate permanent brachytherapy in early-stage prostate cancer: A matched subset analysis. Mol Urol 3:155–160
37.
Zurück zum Zitat Blasko JC, Ragde H, Grimm PD (1997) Potential for neoadjuvant hormonal therapy with brachytherapy for prostate cancer. Mol Urol 1:207–214 Blasko JC, Ragde H, Grimm PD (1997) Potential for neoadjuvant hormonal therapy with brachytherapy for prostate cancer. Mol Urol 1:207–214
38.
Zurück zum Zitat Wallner K, Blasko JC, Dattoli MJ (2001) Prostate brachytherapy made complicated. 2nd edn. Smart-Medicine Press, Seattle, WA Wallner K, Blasko JC, Dattoli MJ (2001) Prostate brachytherapy made complicated. 2nd edn. Smart-Medicine Press, Seattle, WA
39.
Zurück zum Zitat Blasko JC, Grim PD, Sylvester JE (2000) The role of external beam radiotherapy with J-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57:273–278PubMedCrossRef Blasko JC, Grim PD, Sylvester JE (2000) The role of external beam radiotherapy with J-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57:273–278PubMedCrossRef
40.
Zurück zum Zitat Arterbery VE, Wallner K, Roy J, Fuks Z (1993) Short-term morbidity from CT-planned transperineal 125J prostate implants. Int J Radiat Oncol Biol Phys 25:661–665PubMed Arterbery VE, Wallner K, Roy J, Fuks Z (1993) Short-term morbidity from CT-planned transperineal 125J prostate implants. Int J Radiat Oncol Biol Phys 25:661–665PubMed
41.
Zurück zum Zitat Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P (1998) High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 91:91–94 Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P (1998) High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 91:91–94
42.
Zurück zum Zitat Vijverberg PLM, Blank LECM, Dabhoiwala NF, deReijke TM, Koedooder C (1993) Analysis of biopsy findings and implant quality following ultrasonically – guided 125-J implantation for localized prostatic carcinoma. Br J Urol 72:470–477PubMedCrossRef Vijverberg PLM, Blank LECM, Dabhoiwala NF, deReijke TM, Koedooder C (1993) Analysis of biopsy findings and implant quality following ultrasonically – guided 125-J implantation for localized prostatic carcinoma. Br J Urol 72:470–477PubMedCrossRef
43.
Zurück zum Zitat Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59–64PubMed Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S (1999) Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59–64PubMed
44.
Zurück zum Zitat Merrick GS, Butler WM, Lief JH, Dorsey LT (2000) Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47:121–125PubMed Merrick GS, Butler WM, Lief JH, Dorsey LT (2000) Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47:121–125PubMed
45.
Zurück zum Zitat Wallner KE, Roy J, Zelefsky M, Fuks Z, Harrison L (1995) Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 125J prostate brachytherapy. Int J Radiat Oncol Biol Phys 32:465–471PubMedCrossRef Wallner KE, Roy J, Zelefsky M, Fuks Z, Harrison L (1995) Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal 125J prostate brachytherapy. Int J Radiat Oncol Biol Phys 32:465–471PubMedCrossRef
46.
Zurück zum Zitat Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J (1995) Transperineal palladium-103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 45:87–92PubMedCrossRef Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J (1995) Transperineal palladium-103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 45:87–92PubMedCrossRef
47.
Zurück zum Zitat Storey MR, Landgren RC, Cottone JL (1999) Transperineal iodine-125 implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 43:565–571PubMed Storey MR, Landgren RC, Cottone JL (1999) Transperineal iodine-125 implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. Int J Radiat Oncol Biol Phys 43:565–571PubMed
48.
Zurück zum Zitat Talcott JA, Clark JC, Stark P (1999) Long-term treatment-related complications of brachytherapy for early prostate cancer: A survey of treated patients. Proc Annu Meet Am Soc Clin Oncol 18:1196–1205 Talcott JA, Clark JC, Stark P (1999) Long-term treatment-related complications of brachytherapy for early prostate cancer: A survey of treated patients. Proc Annu Meet Am Soc Clin Oncol 18:1196–1205
49.
Zurück zum Zitat Stock RG, Stone NN, Dalal M (2000) Patient reported long-term urinary morbidity and quality of life following 125J prostate brachytherapy. J Urol 163(4, Suppl I):1268 Stock RG, Stone NN, Dalal M (2000) Patient reported long-term urinary morbidity and quality of life following 125J prostate brachytherapy. J Urol 163(4, Suppl I):1268
50.
Zurück zum Zitat Stone NN, Stock RG (2002) Complications following permanent prostate brachytherapy. Eur Urol 41(4):427–433PubMedCrossRef Stone NN, Stock RG (2002) Complications following permanent prostate brachytherapy. Eur Urol 41(4):427–433PubMedCrossRef
51.
Zurück zum Zitat Gelblum DY, Potters L (2000) Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48(1):119–124PubMedCrossRef Gelblum DY, Potters L (2000) Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48(1):119–124PubMedCrossRef
52.
Zurück zum Zitat Snyder KM, Stock RG, Hong SM, LoYc, Stone NN (2001) Defining the risk of developing grade 2 proctitis following 125J prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 50:335–341PubMedCrossRef Snyder KM, Stock RG, Hong SM, LoYc, Stone NN (2001) Defining the risk of developing grade 2 proctitis following 125J prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 50:335–341PubMedCrossRef
53.
Zurück zum Zitat Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ (1999) Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 43:1021–1027PubMedCrossRef Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ (1999) Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 43:1021–1027PubMedCrossRef
54.
Zurück zum Zitat Albert M, Tempany CM, Schultz D, Chen MH, Cormack RA, Kumar S (2003) Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 98(5):949–954PubMedCrossRef Albert M, Tempany CM, Schultz D, Chen MH, Cormack RA, Kumar S (2003) Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 98(5):949–954PubMedCrossRef
55.
Zurück zum Zitat Kaye KW, Olson DJ, Payne JT (1995) Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach. J Urol 153:1020–1025PubMedCrossRef Kaye KW, Olson DJ, Payne JT (1995) Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach. J Urol 153:1020–1025PubMedCrossRef
56.
Zurück zum Zitat Critz FA, Tarlton RS, Holladay DA (1995) Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer 75:2383–2391PubMedCrossRef Critz FA, Tarlton RS, Holladay DA (1995) Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer 75:2383–2391PubMedCrossRef
57.
Zurück zum Zitat Grado GL, Larson TR, Balch CS (1998) Actuarial disease-free survival after prostate brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 42:289–298PubMed Grado GL, Larson TR, Balch CS (1998) Actuarial disease-free survival after prostate brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 42:289–298PubMed
58.
Zurück zum Zitat Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P (1998) High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160:91–95PubMedCrossRef Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P (1998) High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160:91–95PubMedCrossRef
59.
Zurück zum Zitat Kao J, Stock RG, Stone NN (2000) Long-term erectile function following real-time ultrasound-guided brachytherapy for prostate cancer. J Urol 163(4, Suppl I):1276 Kao J, Stock RG, Stone NN (2000) Long-term erectile function following real-time ultrasound-guided brachytherapy for prostate cancer. J Urol 163(4, Suppl I):1276
60.
Zurück zum Zitat Dattoli M, Wallner KE, Cash JC (1996) 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 35:875–879PubMed Dattoli M, Wallner KE, Cash JC (1996) 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 35:875–879PubMed
61.
Zurück zum Zitat Stock RG, Kao J, Stone NN (2001) Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165:436–439PubMedCrossRef Stock RG, Kao J, Stone NN (2001) Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165:436–439PubMedCrossRef
62.
Zurück zum Zitat Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50(5):1235–1242PubMed Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50(5):1235–1242PubMed
63.
Zurück zum Zitat Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62(2):437–447PubMed Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA (2005) Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62(2):437–447PubMed
Metadaten
Titel
Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer
verfasst von
Stefan Machtens
Rolf Baumann
Jörn Hagemann
Antje Warszawski
Andreas Meyer
Johann H. Karstens
Udo Jonas
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2006
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-006-0083-1

Weitere Artikel der Ausgabe 3/2006

World Journal of Urology 3/2006 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.